Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition

Aye,Khin Thenu; Wattanapongpitak,Sakornniya; Supawat,Benjamaporn; Kothan,Suchart; Udomtanakunchai,Chatchanok; Tima,Singkome; Pan,Jie; Tungjai,Montree

doi:10.3892/or.2021.8178

Gallic acid enhances pirarubicin‑induced anticancer in living K562 and K562/Dox leukemia cancer cells through cellular energetic state impairment and P‑glycoprotein inhibition

Authors:
- Khin Thenu Aye
- Sakornniya Wattanapongpitak
- Benjamaporn Supawat
- Suchart Kothan
- Chatchanok Udomtanakunchai
- Singkome Tima
- Jie Pan
- Montree Tungjai
View Affiliations

Affiliations: Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand, Center of Radiation Research and Medical Imaging, Department of Radiologic Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand
Published online on: September 2, 2021 https://doi.org/10.3892/or.2021.8178
Article Number: 227

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leukemia is a common malignancy affecting humans worldwide. Pirarubicin (Pira) is one of the anticancer agents used for the treatment of leukemia. Although Pira is effective, drug resistance may develop in cancer cells exposed to this drug, whereas the combination of natural products with Pira may help to overcome this problem. The aim of the present study was to focus on the effect of gallic acid (GA) on the anticancer activity of Pira in K562 leukemia cells and K562/doxorubicin (Dox)‑resistant leukemia cells in order to investigate the possible underlying mechanisms. The cell viability, mitochondrial activity, mitochondrial membrane potential (ΔΨm) and ATP levels were assessed in living K562 and K562/Dox cancer cells following treatment with GA/Pira combination, GA alone or Pira alone. P‑glycoprotein‑mediated efflux of Pira was determined in GA‑treated K562/Dox cancer cells. The results demonstrated that GA/Pira combination decreased cell viability, mitochondrial activity, ΔΨm and ATP levels in K562 and K562/Dox cancer cells in a GA concentration‑dependent manner compared with non‑treated or Pira‑treated cells. GA inhibited P‑glycoprotein‑mediated efflux of Pira in GA‑treated K562/Dox cancer cells. Therefore, GA enhanced the anticancer effect of Pira on K562 and K562/Dox cancer cells through cellular energy status impairment, and was able to reverse drug resistance in living K562/Dox cancer cells by inhibiting the function of P‑glycoprotein.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 57:727–741. 1999. View Article : Google Scholar : PubMed/NCBI
3	Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
4	Meredith AM and Dass CR: Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 68:729–741. 2016. View Article : Google Scholar : PubMed/NCBI
5	Miller AA and Salewski E: Prospects for pirarubicin. Med Pediatr Oncol. 22:261–268. 1994. View Article : Google Scholar : PubMed/NCBI
6	Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: 4′-O-tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res. 42:1462–1467. 1982.PubMed/NCBI
7	Kunimoto S, Miura K, Takahashi Y, Takeuchi T and Umezawa H: Rapid uptake by cultured tumor cells and intracellular behavior of 4′-O-tetrahydropyranyladriamycin. J Antibiot (Tokyo). 36:312–317. 1983. View Article : Google Scholar : PubMed/NCBI
8	Mizutani H, Hotta S, Nishimoto A, Ikemura K, Miyazawa D, Ikeda Y, Maeda T, Yoshikawa M, Hiraku Y and Kawanishi S: Pirarubicin, an anthracycline anticancer agent, induces apoptosis through generation of hydrogen peroxide. Anticancer Res. 37:6063–6069. 2017.PubMed/NCBI
9	Michieli M, Damiani D, Michelutti A, Candoni A, Masolini P, Scaggiante B, Quadrifoglio F and Baccarani M: Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833. Haematologica. 79:500–507. 1994.PubMed/NCBI
10	Xia Q, Wang ZY, Li HQ, Diao YT, Li XL, Cui J, Chen XL and Li H: Reversion of p-glycoprotein-mediated multidrug resistance in human leukemic cell line by diallyl trisulfide. Evid Based Complement Alternat Med. 2012:7198052012. View Article : Google Scholar : PubMed/NCBI
11	Barrand MA, Bagrij T and Neo SY: Multidrug resistance-associated protein: A protein distinct from P-glycoprotein involved in cytotoxic drug expulsion. Gen Pharmacol. 28:639–645. 1997. View Article : Google Scholar : PubMed/NCBI
12	Choi CH: ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
13	Yang K, Wu J and Li X: Recent advances in the research of P-glycoprotein inhibitors. Biosci Trends. 2:137–146. 2008.PubMed/NCBI
14	Inaba M, Fujikura R, Tsukagoshi S and Sakurai Y: Restored in vitro sensitivity of adriamycin- and vincristine-resistant P388 leukemia with reserpine. Biochem Pharmacol. 30:2191–2194. 1981. View Article : Google Scholar : PubMed/NCBI
15	Mocanu MM, Nagy P and Szöllősi J: Chemoprevention of breast cancer by dietary polyphenols. Molecules. 20:22578–22620. 2015. View Article : Google Scholar : PubMed/NCBI
16	Punia R, Raina K, Agarwal R and Singh RP: Acacetin enhances the therapeutic efficacy of doxorubicin in non-small-cell lung carcinoma cells. PLoS One. 12:e01828702017. View Article : Google Scholar : PubMed/NCBI
17	Liu R, Ji P, Liu B, Qiao H, Wang X, Zhou L, Deng T and Ba Y: Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis. Oncol Lett. 13:1024–1030. 2017. View Article : Google Scholar : PubMed/NCBI
18	Bansal T, Jaggi M, Khar RK and Talegaonkar S: Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. J Pharm Pharm Sci. 12:46–78. 2009. View Article : Google Scholar : PubMed/NCBI
19	Naus PJ, Henson R, Bleeker G, Wehbe H, Meng F and Patel T: Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways. J Hepatol. 46:222–229. 2007. View Article : Google Scholar : PubMed/NCBI
20	Muhammad N, Steele R, Isbell TS, Philips N and Ray RB: Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget. 8:66226–66236. 2017. View Article : Google Scholar : PubMed/NCBI
21	Haslam E and Cai Y: Plant polyphenols (vegetable tannins): Gallic acid metabolism. Nat Prod Rep. 11:41–66. 1994. View Article : Google Scholar : PubMed/NCBI
22	Zhao B and Hu M: Gallic acid reduces cell viability, proliferation, invasion and angiogenesis in human cervical cancer cells. Oncol Lett. 6:1749–1755. 2013. View Article : Google Scholar : PubMed/NCBI
23	Locatelli C, Filippin-Monteiro FB and Creczynski-Pasa TB: Alkyl esters of gallic acid as anticancer agents: A review. Eur J Med Chem. 60:233–239. 2013. View Article : Google Scholar : PubMed/NCBI
24	Priscilla DH and Prince PS: Cardioprotective effect of gallic acid on cardiac troponin-T, cardiac marker enzymes, lipid peroxidation products and antioxidants in experimentally induced myocardial infarction in Wistar rats. Chem Biol Interact. 179:118–124. 2009. View Article : Google Scholar : PubMed/NCBI
25	Lu Z, Nie G, Belton PS, Tang H and Zhao B: Structure-activity relationship analysis of antioxidant ability and neuroprotective effect of gallic acid derivatives. Neurochem Int. 48:263–274. 2006. View Article : Google Scholar : PubMed/NCBI
26	Omóbòwálé TO, Oyagbemi AA, Folasire AM, Ajibade TO, Asenuga ER, Adejumobi OA, Ola-Davies OE, Oyetola O, James G, Adedapo AA and Yakubu MA: Ameliorative effect of gallic acid on doxorubicin-induced cardiac dysfunction in rats. J Basic Clin Physiol Pharmacol. 29:19–27. 2018. View Article : Google Scholar : PubMed/NCBI
27	Kim SH, Jun CD, Suk K, Choi BJ, Lim H, Park S, Lee SH, Shin HY, Kim DK and Shin TY: Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci. 91:123–131. 2006. View Article : Google Scholar : PubMed/NCBI
28	Punithavathi VR, Prince PS, Kumar R and Selvakumari J: Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats. Eur J Pharmacol. 650:465–471. 2011. View Article : Google Scholar : PubMed/NCBI
29	Oyagbemi AA, Omobowale TO, Saba AB, Olowu ER, Dada RO and Akinrinde AS: Gallic acid ameliorates cyclophosphamide-induced neurotoxicity in wistar rats through free radical scavenging activity and improvement in antioxidant defense system. J Diet Suppl. 13:402–419. 2016. View Article : Google Scholar : PubMed/NCBI
30	Supawat B, Moungthong P, Chanloi C, Jindachai N, Tima S, Kothan S, Udomtanakunchai C and Tungjai M: Effects of gadolinium-based magnetic resonance imaging contrast media on red blood cells and K562 cancer cells. J Trace Elem Med Biol. 62:1266402020. View Article : Google Scholar : PubMed/NCBI
31	Aborehab NM and Osama N: Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells. Cancer Cell Int. 19:1542019. View Article : Google Scholar : PubMed/NCBI
32	Gu R, Zhang M, Meng H, Xu D and Xie Y: Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition. Biomed Pharmacother. 105:491–497. 2018. View Article : Google Scholar : PubMed/NCBI
33	Liao CC, Chen SC, Huang HP and Wang CJ: Gallic acid inhibits bladder cancer cell proliferation and migration via regulating fatty acid synthase (FAS). J Food Drug Anal. 26:620–627. 2018. View Article : Google Scholar : PubMed/NCBI
34	Liu Z, Li D, Yu L and Niu F: Gallic acid as a cancer-selective agent induces apoptosis in pancreatic cancer cells. Chemotherapy. 58:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
35	Tang HM and Cheung PCK: Gallic acid triggers iron-dependent cell death with apoptotic, ferroptotic, and necroptotic features. Toxins (Basel). 11:4922019. View Article : Google Scholar : PubMed/NCBI
36	Wang K, Zhu X, Zhang K, Zhu L and Zhou F: Investigation of gallic acid induced anticancer effect in human breast carcinoma MCF-7 cells. J Biochem Mol Toxicol. 28:387–393. 2014. View Article : Google Scholar : PubMed/NCBI
37	Weng SW, Hsu SC, Liu HC, Ji BC, Lien JC, Yu FS, Liu KC, Lai KC, Lin JP and Chung JG: Gallic acid induces DNA damage and inhibits DNA repair-associated protein expression in human oral cancer SCC-4 cells. Anticancer Res. 35:2077–2084. 2015.PubMed/NCBI
38	Kothan S, Dechsupa S, Leger G, Moretti JL, Vergote J and Mankhetkorn S: Spontaneous mitochondrial membrane potential change during apoptotic induction by quercetin in K562 and K562/adr cells. Can J Physiol Pharmacol. 82:1084–1090. 2004. View Article : Google Scholar : PubMed/NCBI
39	Tungjai M, Phathakanon N and Rithidech KN: Effects of medical diagnostic Low-dose X rays on human lymphocytes: Mitochondrial membrane potential, apoptosis and cell cycle. Health Phys. 112:458–464. 2017. View Article : Google Scholar : PubMed/NCBI
40	Supawat B, Udomtanakunchai C, Kothan S and Tungjai M: The effects of iodinated radiographic contrast media on multidrug-resistant K562/Dox cells: Mitochondria impairment and P-glycoprotein inhibition. Cell Biochem Biophys. 77:157–163. 2019. View Article : Google Scholar : PubMed/NCBI
41	Yang NC, Ho WM, Chen YH and Hu ML: A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP. Anal Biochem. 306:323–327. 2002. View Article : Google Scholar : PubMed/NCBI
42	Reungpatthanaphong P and Mankhetkorn S: Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull. 25:1555–1561. 2002. View Article : Google Scholar : PubMed/NCBI
43	Garnier-Suillerot A, Marbeuf-Gueye C, Salerno M, Loetchutinat C, Fokt I, Krawczyk M, Kowalczyk T and Priebe W: Analysis of drug transport kinetics in multidrug-resistant cells: Implications for drug action. Curr Med Chem. 8:51–64. 2001. View Article : Google Scholar : PubMed/NCBI
44	Frézard F, Pereira-Maia E, Quidu P, Priebe W and Garnier-Suillerot A: P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. Eur J Biochem. 268:1561–1567. 2001. View Article : Google Scholar : PubMed/NCBI
45	Bai J, Zhang Y, Tang C, Hou Y, Ai X, Chen X, Zhang Y, Wang X and Meng X: Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases. Biomed Pharmacother. 133:1109852021. View Article : Google Scholar : PubMed/NCBI
46	Bhattacharya S, Muhammad N, Steele R, Peng G and Ray RB: Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth. Oncotarget. 7:33202–33209. 2016. View Article : Google Scholar : PubMed/NCBI
47	Sun J, Chu YF, Wu X and Liu RH: Antioxidant and antiproliferative activities of common fruits. J Agric Food Chem. 50:7449–7454. 2002. View Article : Google Scholar : PubMed/NCBI
48	Dai J and Mumper RJ: Plant phenolics: Extraction, analysis and their antioxidant and anticancer properties. Molecules. 15:7313–7352. 2010. View Article : Google Scholar : PubMed/NCBI
49	De A, De A, Papasian C, Hentges S, Banerjee S, Haque I and Banerjee SK: Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors. PLoS One. 8:e727482013. View Article : Google Scholar : PubMed/NCBI
50	Subramanian AP, Jaganathan SK, Mandal M, Supriyanto E and Muhamad II: Gallic acid induced apoptotic events in HCT-15 colon cancer cells. World J Gastroenterol. 22:3952–3961. 2016. View Article : Google Scholar : PubMed/NCBI
51	Sourani ZM, Pourgheysari BP, Beshkar PM, Shirzad HP and Shirzad MM: Gallic acid inhibits proliferation and induces apoptosis in lymphoblastic leukemia cell line (C121). Iran J Med Sci. 41:525–530. 2016.PubMed/NCBI
52	Yoshino M, Haneda M, Naruse M, Htay HH, Iwata S, Tsubouchi R and Murakami K: Prooxidant action of gallic acid compounds: Copper-dependent strand breaks and the formation of 8-hydroxy-2′-deoxyguanosine in DNA. Toxicol In Vitro. 16:705–709. 2002. View Article : Google Scholar : PubMed/NCBI
53	Wang R, Ma L, Weng D, Yao J, Liu X and Jin F: Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway. Oncol Rep. 35:3075–3083. 2016. View Article : Google Scholar : PubMed/NCBI
54	Rajagopalan R, Jain SK and Trivedi P: Synergistic anti-cancer activity of combined 5-fuorouracil and gallic acid-stearylamine conjugate in a431 human squamous carcinoma cell line. Trop J Pharm Res. 18:471–477. 2019. View Article : Google Scholar
55	Gillet JP, Efferth T and Remacle J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta. 1775:237–262. 2007.PubMed/NCBI
56	Mimeault M, Hauke R and Batra SK: Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther. 83:673–691. 2008. View Article : Google Scholar : PubMed/NCBI
57	Mankhetkorn S and Garnier-Suillerot A: The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake. Eur J Pharmacol. 343:313–321. 1998. View Article : Google Scholar : PubMed/NCBI
58	Kitagawa S, Nabekura T, Kamiyama S, Takahashi T, Nakamura Y, Kashiwada Y and Ikeshiro Y: Effects of alkyl gallates on P-glycoprotein function. Biochem Pharmacol. 70:1262–1266. 2005. View Article : Google Scholar : PubMed/NCBI